Takeda Vaccines, Inc.
Records under this name other than the patents Takeda Vaccines, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 57 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,821,049 | Method of conferring a protective immune response to Norovirus Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,052,374 | Compositions, Methods and Uses for Dengue Virus SEROTYPE-4 Constructs Held by another company In force · High confidence | In force | High confidence | |
| US 9,408,901 | Compositions, Methods and Uses for Dengue Virus SEROTYPE-4 Constructs Formerly held In force · High confidence | In force | High confidence | |
| US 10,130,696 | Method of Conferring a Protective Immune Response to Norovirus Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 9,834,757 | Hand, foot, and mouth vaccines and methods of manufacture and use thereof Lapsed on the fee record Ended Dec 5, 2025 · USPTO record | Lapsed on the fee record | Ended Dec 5, 2025 | USPTO record |
| US 10,806,781 | Compositions and methods for live, attenuated alphavirus formulations Lapsed on the fee record Ended Oct 20, 2024 · USPTO record | Lapsed on the fee record | Ended Oct 20, 2024 | USPTO record |
| US 10,806,782 | Hand, foot, and mouth vaccines and methods of manufacture and use thereof Lapsed on the fee record Ended Oct 20, 2024 · USPTO record | Lapsed on the fee record | Ended Oct 20, 2024 | USPTO record |
| US 10,632,184 | Compositions and methods for stabilizing alphaviruses with improved formulations Lapsed on the fee record Ended Apr 28, 2024 · USPTO record | Lapsed on the fee record | Ended Apr 28, 2024 | USPTO record |
| US 9,028,809 | Compositions, methods and uses for expression of enterobacterium-associated peptides Lapsed on the fee record Ended May 12, 2023 · USPTO record | Lapsed on the fee record | Ended May 12, 2023 | USPTO record |
| US 9,011,874 | Compositions, methods and uses for poxvirus elements in vaccine constructs Lapsed on the fee record Ended Apr 21, 2023 · USPTO record | Lapsed on the fee record | Ended Apr 21, 2023 | USPTO record |